A detailed history of G&S Capital LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, G&S Capital LLC holds 653 shares of VRTX stock, worth $303,357. This represents 0.13% of its overall portfolio holdings.

Number of Shares
653
Previous 653 -0.0%
Holding current value
$303,357
Previous $306,000 0.98%
% of portfolio
0.13%
Previous 0.13%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

SELL
$392.81 - $485.53 $14,141 - $17,479
-36 Reduced 5.22%
653 $306,000
Q1 2024

Apr 15, 2024

SELL
$407.69 - $446.08 $3,261 - $3,568
-8 Reduced 1.15%
689 $288,000
Q4 2023

Jan 26, 2024

SELL
$343.0 - $410.68 $51,107 - $61,191
-149 Reduced 17.61%
697 $283,000
Q2 2023

Jul 26, 2023

SELL
$314.42 - $351.91 $154,694 - $173,139
-492 Reduced 36.77%
846 $297,000
Q1 2023

Apr 20, 2023

SELL
$283.23 - $323.1 $19,542 - $22,293
-69 Reduced 4.9%
1,338 $421,000
Q4 2022

Jan 20, 2023

BUY
$285.76 - $321.48 $402,064 - $452,322
1,407 New
1,407 $0
Q3 2020

Oct 21, 2020

SELL
$255.65 - $303.1 $271,755 - $322,195
-1,063 Closed
0 $0
Q2 2020

Jul 24, 2020

BUY
$225.48 - $295.8 $239,685 - $314,435
1,063 New
1,063 $309,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track G&S Capital LLC Portfolio

Follow G&S Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of G&S Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on G&S Capital LLC with notifications on news.